The Global Alliance for TB Drug Development (TB Alliance) is a product development partnership (PDP), working to develop new, simpler, faster-acting TB treatments. As a PDP, the not-for-profit TB Alliance builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new TB treatments for underserved markets. Through its unique, collaborative efforts, the TB Alliance is able to leverage innovation to advance the science, access a variety of funding sources, and apply a wide range of tools and knowledge to its programs.

Before TB Alliance was established in 2000, there were no clinical-stage TB drugs in the pipeline—and no hope on the horizon for better TB regimens for patients. However, the organization has been able to catalyze and advance the field. Today, working with public and private partners worldwide, TB Alliance is leading the development of the largest portfolio of TB drug candidates in history with the commitment to ensure that approved new TB drug regimens are affordable, adopted, and available to those who need them.

**TB Alliance Pharmaceutical Partnerships**

TB Alliance currently has partnerships with many of the world’s largest pharmaceutical companies, under which it manages more than 20 projects in development, including three drug candidates in clinical trials. Current TB Alliance pharmaceutical partners include:

- AstraZeneca
- Bayer
- GlaxoSmithKline
- Novartis
- Sanofi-Aventis
- Johnson & Johnson/Tibotec

**TB Alliance Public Research Institutes & Non-Governmental Institutions**

TB Alliance engages collaborators from public research and non-governmental institutions, including several in China, to find promising drugs, including:

- Beijing Tuberculosis and Thoracic Tumor Research Institute
- Indian Council of Scientific and Industrial Research
- Institute of Materia Medica
- International Scientific Exchange Foundation of China
- Novartis Institute for Tropical Diseases
- Scripps Research Institute

**TB Alliance Academic Partnerships**

TB Alliance also engages academia and universities to help lead the development of the tuberculosis drug portfolio. These partnerships are critical to advance early research and discovery efforts and include the following:

- Johns Hopkins University
- New York Medical College
- University of Auckland
- University of Pennsylvania School of Medicine
- Yonsei University
The Critical Path to TB Drug Regimens (CPTR)

The Critical Path to TB Drug Regimens (CPTR) is a broad collaboration of pharmaceutical companies, civil society organizations, and others working to dramatically accelerate the development of new, safe, and highly effective combination treatments for TB – and replace an almost 50-year-old drug regimen. Launched in May 2010 by TB Alliance, the Bill & Melinda Gates Foundation and the Critical Path Institute, the initiative is championing an innovative model pioneered by the TB Alliance to test TB drugs concurrently, with the chance to reduce the time it takes to develop an innovative regimen by 75 percent.

Following is a list of participating organizations:
- Anacor Pharmaceuticals
- AstraZeneca
- Bayer
- Bill & Melinda Gates Foundation
- Critical Path Institute
- European Developing Clinical Trials Partnership
- GlaxoSmithKline
- Johnson & Johnson
- Pfizer
- Otsuka
- Sanofi Aventis
- Sequella
- Novartis
- TB Alliance
- Treatment Action Group
- Vertex

In a keynote address at the launch of CPTR, U.S. FDA Commissioner Dr. Margaret Hamburg applauded the initiative’s partners for their commitment to innovation, and pledged the FDA’s support to act as a “gateway” and not a barrier to the development of innovative, improved, and urgently needed TB regimens. These innovative regimens are desperately needed to tackle drug-sensitive and drug-resistant tuberculosis. Other regulators around the world have also shown their support for combination drug testing.

Our Stakeholder Organizations

Our Stakeholder institutions advise, guide, and support the efforts of the Global Alliance for TB Drug Development. TB Alliance’s Stakeholders Association includes a range of institutions worldwide that share a clear interest, and a significant stake, in ensuring the development of a faster, better cure for tuberculosis. They include representatives from developing nations, government, NGOs, professional organizations, academia, foundations, and industry.

We thank our partners and donors for their support and work to advance promising new tuberculosis drug regimens.